Optomed Plc: Half-year Report, January – June 2023

Report this content

Optomed Plc Stock Exchange Release 4 August 2023 at 9.00, Helsinki

Optomed Plc: Half-year Report, January – June 2023

April – June 2023

  • Revenue increased by 0.3 percent to EUR 3.7 (3.7) million.
  • Devices segment revenue decreased by 6.5 percent to EUR 1.3 (1.4) million due to a slow quarter of the OEM and Chinese sales channels.
  • Software segment revenue increased by 4.2 percent to EUR 2.5 (2.4) million driven by strong healthcare solution sales.
  • EBITDA amounted to EUR -0.5 (-0.8) million corresponding to -12.4 (-21.8) percent of revenue, continuing the positive trend from previous quarters.​
  • After the review period on 3 August 2023 Optomed announced that Juho Himberg will start as Optomed’s CEO 1 October 2023. Previously Juho Himberg has served as the CEO of Aidian (former Orion Diagnostica), a leading point-of-care diagnostics company with innovative products and services for improving the well-being and quality of life for people around the world. Prior to Aidian, Juho has held several leadership positions globally in healthcare and medical technology companies such as Orton, Stryker, C.R. Bard Inc. and Gambro. The CEO transition plan was announced 14 June 2023. Optomed's current CEO Seppo Kopsala and the Board of Directors have agreed that Kopsala will leave the CEO position once the new CEO is ready to start.
  • Outlook unchanged: Optomed expects its full year 2023 revenue to grow compared to 2022.
  • Aurora AEYE FDA clearance process: data collection continues.

January – June 2023

  • Revenue increased by 4.0 percent to EUR 7.2 (6.9) million.
  • Devices segment revenue decreased by 10.9 percent to EUR 2.2 (2.4) million.
  • Software segment revenue increased by 11.9 percent to EUR 5.1 (4.5) million.
  • Adjusted EBITDA amounted to EUR -976 (-1,750) thousand corresponding to -13.5 (-25.2) percent of revenue.


Key figures

EUR, thousand

Q2/2023

Q2/2022

Change, %

H1/2023

H1/2022

Change, %

2022

Revenue

3,744

3,733

0.3%

7,222

6,947

4.0%

14,660

Gross profit *

2,486

2,149

15.7%

4,962

4,339

14.4%

10,069

Gross margin % *

66.4%

57.6%

68.7%

62.4%

68.7%

EBITDA

-462

-813

43.1%

-976

-1,750

44.2%

-1,952

EBITDA margin *, %

-12.4%

-21.8%

-13.5%

-25.2%

-13.3%

Adjusted EBITDA *

-462

-813

43.1%

-976

-1,750

44.2%

-1,952

Adjusted EBITDA margin *, %

-12.4%

-21.8%

-13.5%

-25.2%

-13.3%

Operating result (EBIT)

-1,009

-1,355

25.5%

-2,052

-2,815

27.1%

-5,097

Operating margin (EBIT) *, %

-27.0%

-36.3%

-28.4%

-40.5%

-34.8%

Adjusted operating result (EBIT) *

-1,009

-1,355

25.5%

-2,052

-2,815

27.1%

-5,097

Adjusted operating margin (EBIT margin) *, %

-27.0%

-36.3%

-28.4%

-40.5%

-34.8%

Net profit/ loss

-1,314

-1,328

1.1%

-2,471

-2,698

8.4%

-5,472

Earnings per share

-0.08

-0.10

13.0%

-0.16

-0.20

19.5%

-0.37

Cash flow from operating activities

-468

-965

51.5%

-913

-1,665

45.2%

-2,370

Net Debt

-883

-825

7.1%

-883

-825

7.1 %

-3,251

Net debt/ Adjusted EBITDA (LTM)

0.7

0.2

0.7

0.2

1.7

Equity ratio  *

63.6%

61.5%

63.6%

61.5%

65.0%

R&D expenses personnel

362

222

63.3%

645

598

7.9%

1,198

R&D expenses other costs

150

147

2.5%

313

356

-12.0%

661

Total R&D expenses

512

368

39.1%

958

954

0.5%

1,859

*) Alternative performance measures, see section Alternative Performance Measures for definitions and calculations.

CEO Review

Software segment and profitability continues to grow.

The sales growth of Optomed's Software business unit continued, driven by new healthcare software solution deliveries and increased recurring business. In addition to revenue growth, the Software Segment’s profitability was very good during the review period. Similar to previous quarters, we are highly satisfied with this development, as it enables significant investments in launching new products into the market and expanding into the US market.

The Devices Segment that is currently in a transitional phase, had a relatively quiet quarter, although the gap from the comparison period of the previous year was not as significant as in the previous quarter. Sales of devices under our own brand, particularly through our international distribution channels, showed strong growth once again. However, OEM sales declined significantly compared to the previous year. As a result, the Devices Segment's sales slightly decreased compared to the comparison period. The trend where the number of devices sold under our own brand grows more than OEM sales in the Devices Segment, continued strongly during the quarter. This shift in trend has recently had a negative impact on revenue development but a positive effect on sales margins.

We are confident that our products are highly competitive and well-positioned in the global market. Our pipeline has expanded, including significant organizational tenders in multiple markets. With these initiatives, we anticipate a return to a growth trajectory for the Device's segment, driving revenue growth. Currently, our primary focus is on advancing the FDA approval process for the AI fundus camera Aurora AEYE, which is our most significant ongoing project. We are making progress during the review period and are approaching our target. However, until we have official updates to share, we will refrain from providing further comments on this matter. We have a good understanding of the FDA's expectations and are confident that we can meet them with the ongoing measures we have in place. Additionally, another important project for the company is the completion of the new device development project, which is currently in the CE approval phase.

The company's profitability and cash flow development continue positively. This is influenced by growing and profitable software sales, Devices segments improving sales margins, significant investment projects in their final stages, and declining fixed costs. Our products are technically excellent and competitive, and the development pipeline for new products is strong. The anticipated FDA clearance for AI fundus camera Aurora AEYE that we are targeting will be an extremely significant breakthrough for the company when it materializes.

I am satisfied with the current situation of the company and optimistic about its future prospects. The company and organization are ready to start the next phase.

Seppo Kopsala

CEO

Outlook 2023


Optomed expects its full year 2023 revenue to grow compared to 2022.

Telephone conference


A telephone conference for analysts, investors and media will be arranged on 4 August 2023 at 11.00 EET, (10.00 CET). The event will be held in English. The presentation material will be available at www.optomed.com/investors 10.00 EET at the latest.

The participants are requested to register for the call-in advance by email to sakari.knuutti@optomed.com.

Please see the call-in numbers below:

FI +358 9 856 263 00

SE +46 8 505 218 52

UK +44 20 3321 5273

US +1 646 838 1719

FR +33 1 70 99 53 92

The conference id is 179 385 659#

Please note that by dialing into the conference call, the participant agrees that personal information such as name and company name will be collected.

Group performance

April – June 2023

In April-June 2023, Group revenue increased by 0.3 percent to EUR 3,744 (3,733) thousand. Devices segment revenue decreased by 6.5 percent to EUR 1,273 (1,361) thousand in spite of strong performance of the global distributor sales as the OEM channel had a slow quarter. The Software segment revenue increased by 4.2 percent  to EUR 2,471 (2,372) thousand as the healthcare solution sales continued to perform well.

In April-June 2023, the gross margin increased to 66.4 from 57.6 percent of last year as both segments improved their margins. The increase was mainly driven by the improved profitability of the healthcare solution sales.

EBITDA improved and it was EUR -462 (-813) thousand. The key driver for the improved EBITDA was improved gross profit, however, the OPEX decreased as well.

In April-June 2023, net financial items amounted to EUR -325 (6) thousand and consisted mainly of interest payments to financial institutions and the translation effect of Chinese RMB and USD to EUR.

January – June 2023

In January-June 2023, Group revenue increased by 4.0 percent to EUR 7,222 (6,947) thousand. The growth was driven by the Software segment as the Devices segment’s revenue decreased by 10.9 percent while the Software segment’s revenue increased by 11.9 percent.

The gross margin increased to 68.7 percent from 62.4 percent last year.

EBITDA amounted to EUR -976 (-1,750) thousand and EBIT was EUR -2,052 (-2,815) thousand. The improvement is due to the combination of improved gross profit and decreased OPEX.

Net financial items amounted to EUR -459 (77) thousand and consisted mainly of interest payments to financial institutions and the translation effect of Chinese RMB to EUR.

Cash flow and financial position

April – June 2023

In April-June 2023, the cash flow from operating activities amounted to EUR -468 (-965) thousand. Net cash used in investing activities was EUR -668 (-825) thousand and relates to capitalized development expenses. Net cash from financing activities amounted to EUR -348 (4,208) thousand.

Consolidated cash and cash equivalents at the end of the period amounted to EUR 5,691 (7,097) thousand. Interest-bearing net debt totalled EUR -883 (-825) thousand at the end of the period.

Net working capital was EUR 3,537 (4,239) thousand at the end of the period.

The Chinese customer that Optomed has large due trade receivables from continued to pay as scheduled.

January – June 2023

In January-June 2023, the cash flow from operating activities amounted to EUR -913 (-1,665) thousand.

Net cash used in investing activities was EUR -1,213 (-1,672) thousand and relates to capitalized development expenses.

Net cash from financing activities amounted to EUR -696 (3,595) thousand.

Devices segment

Optomed has two synergistic business segments: Devices and Software.

The Devices segment develops, commercializes, and manufactures easy-to-use, and affordable handheld fundus cameras, that are suitable for any clinic for screening of various eye diseases, such as diabetic retinopathy, glaucoma and AMD (Age Related Macular Degeneration).

EUR, thousand

Q2/2023

Q2/2022

Change, %

H1/2023

H1/2022

Change, %

2022

Revenue

1,273

1,361

-6.5%

2,161

2,425

-10.9%

5,398

Gross profit *

674

642

5.0%

1,233

1,283

-3.9%

3,738

Gross margin % *

53.0%

47.2%

57.0%

52.9 %

69.3%

EBITDA

-217

-464

53.2%

-643

-963

33.2%

-670

EBITDA margin *, %

-17.1%

-34.1%

-29.8%

-39.7 %

-12.4%

Operating result (EBIT)

-578

-843

31.5%

-1,356

-1,707

20.5%

-3,159

Operating margin (EBIT) *, %

-45.4%

-61.9%

-62.8%

-70.4 %

-58.5%

*) Alternative performance measures, see section Alternative Performance Measures for definitions and calculations.
 


 

April-June 2023

In April-June 2023, the Devices segment revenue decreased by 6.5 percent to EUR 1,273 (1,361) thousand due to softness of the OEM channel. The global distributor sales continued to perform well.

The gross margin was 53.0 (47.2) percent. EBITDA was EUR -217 (-464) thousand or -17.1 (-34.1) percent of revenue. During the quarter, Optomed took actions to reduce operating costs especially in the support functions affecting both the Devices segment and the group functions.

January-June 2023

In January-June 2023, the Devices segment revenue decreased by 10.9 percent to EUR 2,161 (2,425) thousand.

The gross margin increased to 57.0 percent from 52.9 percent as the share of higher gross margin global distributor sales has increased compared to lower margin OEM sales.

EBITDA was EUR -643 (-963) thousand or -29.8 (-39.7) percent of revenue.

Software segment

Optomed has two synergistic business segments: Devices and Software.

The Software segment develops and commercializes screening software for diabetic retinopathy and cancer screening for healthcare organizations. The segment also distributes off-the-shelf products from selected partners to supplement its own solutions and expertise and provides software consultation to support the Devices segment screening solution projects.

EUR, thousand

Q2/2023

Q2/2022

Change, %

H1/2023

H1/2022

Change, %

2022

Revenue

2,471

2,372

4.2%

5,061

4,522

11.9%

9,263

Gross profit *

1,812

1,507

20.2%

3,729

3,056

22.0%

6,330

Gross margin % *

73.3%

63.5%

73.7%

67.6%

68.3%

EBITDA

578

478

20.7%

1,368

898

52.2%

2,079

EBITDA margin *, %

23.4%

20.2%

27.0%

19.9%

22.4%

Operating result (EBIT)

393

317

24.2%

1,009

580

74.0%

1,431

Operating margin (EBIT) *, %

15.9%

13.3%

19.9%

12.8%

15.4%

*) Alternative performance measures, see section Alternative Performance Measures for definitions and calculations.

 

April – June 2023

In April-June 2023, the Software segment revenue increased by 4.2 percent to EUR 2,471 (2,372) thousand as the healthcare solutions business continued on its growth track.

The profitability improved due to good performance of the healthcare solution sales. Gross margin increased and was 73.3 (63.5) percent. EBITDA was EUR 578 (478) thousand or 23.4 (20.2) percent of revenue.

January – June 2023

In January-June 2023, the Software segment revenue increased by 11.9 percent to EUR 5,061 (4,522) thousand.

Gross margin increased and it was 73.3 (63.5) percent. EBITDA was EUR 1,368 (898) thousand or 27.0 (19.9) percent of revenue. The increased profitability was driven by improved performance of the healthcare solution sales.

Group-wide expenses

Group-wide expenses relate to functions supporting the entire group such as treasury, group accounting, marketing, legal, HR, and IT.

April – June 2023

Group-wide operating expenses amounted to EUR 823 (827) thousand.

January – June 2023

Group-wide operating expenses amounted to EUR 1,700 (1,685) thousand.

Personnel

Number of personnel at the end of the reporting period.

6/2023

6/2022

Devices

47

55

Software

46

43

Group common

22

22

Total

115

120

Corporate Governance

Optomed complies with Finnish laws and regulations, Optomed’s Articles of Association, the rules of Nasdaq Helsinki and the Finnish Corporate Governance Code 2020 issued by the Securities Market Association of Finland. The code is publicly available at http://cgfinland.fi/en/. Optomed’s corporate governance statement 2022 is available on the company website www.optomed.com/investors/.

Annual General Meeting

The Annual General Meeting held on 10 May 2023 adopted the financial statements for the financial period ended on 31 December 2022 and discharged the members of the Board of Directors and the CEO from liability for the financial period ended on 31 December 2022. The Annual General Meeting decided to reject the remuneration report for governing bodies. The decision made is advisory.

The Annual General Meeting resolved in accordance with the proposal of the Board of Directors that no dividend will be paid for the year 2022.

The number of members of the Board of Directors was confirmed as six. Seppo Mäkinen, Petri Salonen, Reijo Tauriainen and Anna Tenstam were re-elected as members of the Board and Catherine Calarco and Ty Lee were elected as new members of the Board.

The Annual General Meeting confirmed the annual Board remuneration as follows:

  • Chairman of the Board EUR 36,000
  • members of the Board EUR 18,000.

In addition, a meeting fee in the amount of EUR 300 is paid to the Chairpersons and EUR 200 to members of the Committees for each Committee meeting. 40 percent of the Board remuneration is paid in Optomed shares and 60 percent in cash. The remuneration will be paid once a year in August, after Optomed’s H1 report has been announced.

The Annual General Meeting decided to re-elect KPMG Oy Ab, a firm of authorized public accountants, as the Company’s auditor. KPMG Oy Ab has informed the Company that Authorized Public Accountant Heidi Hyry acts as the auditor with principal responsibility. Auditor’s remuneration will be paid in accordance with an invoice approved by the Company.

The Annual General Meeting approved the authorization for the Board of Directors to repurchase Optomed’s own shares and to accept them as pledge. Altogether no more than 1,654,135 shares may be repurchased or accepted as pledge. The authorization will be valid until the earlier of the end of the next Annual General Meeting or 18 months from the resolution of the Annual General Meeting.

The Annual General Meeting authorized the Board of Directors to decide on the issuance of shares and other special rights entitling to shares referred to in Chapter 10, Section 1 of the Finnish Companies Act. The number of shares to be issued based on this authorization may not exceed 1,654,135. The Board of Directors is authorized to resolve on all terms and conditions of the issuance of shares and special rights entitling to shares, including the right to derogate from the pre-emptive right of the shareholders. The authorization will be valid until the earlier of the end of the next Annual General Meeting or 18 months from the resolution of the Annual General Meeting.

The Annual General Meeting decided to amend the Articles of Association so that the minimum number of the members of the Board of Directors was reduced from five members to four.

Decisions of the Board of Directors:

At its meeting held after the Annual General Meeting, the Board of Directors elected from among its members Petri Salonen as its Chairman. The committee members were elected as follows:

Audit Committee:

  • Reijo Tauriainen (Chairman)
  • Catherine Calarco
  • Anna Tenstam

Remuneration Committee:

  • Seppo Mäkinen (Chairman)
  • Catherine Calarco
  • Ty Lee

Shares and shareholders

The Company has one share series with all shares having the same rights. At the end of the review period Optomed Plc's share capital consisted of 16,541,355 shares and the Company held 370,066 shares in the treasury which approximately corresponds to 2.3 percent of the total amount of the shares and votes. Additional information with respect to the shares, shareholding and trading can be found on the Company’s website www.optomed.com/investors/.

Risks and uncertainties

The key risks and uncertainties are described in the company’s Annual Report 2022 which was published on 2 March 2023. The complete report is available at https://www.optomed.com/investors/. The risk position of Optomed has not changed since then.

Flagging notifications

5 June 2023 Cenova Capital notified that its total holdings in Optomed shares and votes has decreased to 9.96% of all of the registered shares in Optomed.

Audit review

This financial report has not been audited by the company's auditors.

Financial reporting in 2023

  • 3 November 2023 Interim Report for 1 January – 30 September 2023

For more information, contact

Sakari Knuutti, CFO

Tel: +358 (0)50 562 4077

E-mail: sakari.knuutti@optomed.com 

Seppo Kopsala, CEO

Tel: +358 (0)40 555 1050

E-mail:  seppo.kopsala@optomed.com

About Optomed

Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras and screening software. Optomed combines handheld screening devices with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye-screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries.

www.optomed.com

Alternative Performance Measures

Optomed uses certain alternative performance measures (APMs) with the purpose to provide a better understanding of how the business develops. These APMs, as defined, cannot be fully compared with other companies’ APMs.

Alternative Performance Measures

Definition

Gross profit

Revenue + Other operating income – Materials and services expenses

Gross margin, %

Gross profit / Revenue

EBITDA

Operating result before depreciation, amortization and impairment losses

EBITDA margin, %

EBITDA / Revenue

Operating result

Profit/loss after depreciation, amortization and impairment losses

Operating margin, %

Operating result / Revenue

Adjusted operating result

Operating result excluding items affecting comparability

Adjusted operating margin, %

Adjusted operating result / Revenue

Adjusted EBITDA

EBITDA excluding items affecting comparability

Adjusted EBITDA margin, %

Adjusted EBITDA / Revenue

Items affecting comparability

Material items outside ordinary course of business including restructuring costs, net gains or losses from sale of business operations or other non-current assets, strategic development projects, external advisory costs related to capital reorganisation, impairment charges on non-current assets incurred in connection with restructurings, compensation for damages and transaction costs related to business acquisitions.

Net Debt

Interest-bearing liabilities (borrowings from financial institutions, government loans and subordinated loans) – cash and cash equivalents (excl. lease liabilities according to IFRS 16)

Net Debt / Adjusted EBITDA (LTM), times

Net Debt / Adjusted EBITDA (for the last twelve months, LTM)

Earnings per share

Net result / Weighted average number of outstanding shares

Equity ratio, %

Total equity / Total assets

R&D expenses

Employee benefit expenses for R&D personnel and other operational expenses related to R&D activities

Consolidated income statement

In thousands of euro

Q2/2023

Q2/2022

H1/2023

H1/2022

 2022

Revenue

3,744

3,733

7,222

6,947

14,660

Other operating income

34

0

34

37

857

Materials and services

-1,292

-1,584

-2,294

-2,645

-5,449

Employee benefit expenses

-2,190

-2,124

-4,382

-4,367

-8,827

Depreciation, amortization and Impairment losses

-547

-542

-1,076

-1,066

-3,145

Other operating expenses

-758

-838

-1,556

-1,722

-3,193

Operating result

-1,009

-1,355

-2,052

-2,815

-5,097

Finance income

38

302

106

418

569

Finance expenses

-363

-296

-565

-340

-1,024

Net finance expenses

-325

6

-459

77

-454

Profit (loss) before income taxes

-1,334

-1,348

-2,511

-2,738

-5,551

Income tax expense

20

20

40

39

79

Loss for the period

-1,314

-1,328

-2,471

-2,698

-5,472

Loss for the period attributable to

Owners of the parent company

-1,314

-1,328

-2,471

-2,698

-5,472

Loss per share attributable to owners of
the parent company

Weighted average number of shares

15,691,727

13,797,968

15,691,727

13,797,968

14,640,697

Basic loss per share (euro)

-0.08

-0.10

-0.16

-0.20

-0.37


Consolidated condensed comprehensive income statement

In thousands of euro

Q2/2023

Q2/2022

H1/2023

H1/2022

2022

Loss for the period

-1,314

-1,328

-2,471

-2,698

-5,472

Other comprehensive income

Foreign currency translation difference

166

-43

244

-120

139

Other comprehensive income, net of tax

166

-43

244

-120

139

Total comprehensive loss attributable to Owners of the parent company

-1,148

-1,372

-2,227

-2,818

-5,333

Consolidated balance sheet

In thousands of euro

June 30, 2023

June 30, 2022

Dec 31, 2022

ASSETS

Non-current assets

Goodwill

 4,256

 4,256

 4,256

Development costs

 7,200

 7,115

 6,562

Customer relationships

 1,053

 1,275

 1,164

Technology

 483

 585

 534

Other intangible assets

 381

 355

 379

Total intangible assets

 13,374

 13,586

 12,895

Tangible assets

 769

 664

 852

Right-of-use assets

 1,231

 1,029

 1,448

Deferred tax assets

 17

 14

 15

Total non-current assets

 15,391

 15,293

 15,210

Current assets

Inventories

 2,954

3,161

 2,998

Trade and other receivables

4,590

5,190

4,568

Cash and cash equivalents

 5,691

 7,079

 8,524

Total current assets

 13,235

 15,429

 16,090

Total assets

 28,627

 30,722

 31,300

In thousands of euro

June 30, 2023

June 30, 2022

Dec 31, 2022

EQUITY

Share capital

 80

 80

 80

Share premium

 504

 504

 504

Reserve for invested non-restricted equity

 46,912

 43,089

 46,896

Translation differences

296

-207

51

Retained earnings

-27,117

-21,879

-21,717

Profit (loss) for the financial year

-2,471

-2,698

-5,472

Total equity

 18,203

 18,888

 20,342

LIABILITIES

Non-current liabilities

Borrowings from financial institutions

 2,983

 3,822

 3,380

Government loans

 837

 1,871

 906

Lease liabilities

 744

 640

 1,058

Deferred tax liabilities

 349

 425

 387

Total Non-current liabilities

 4,913

 6,758

 5,731

Current liabilities

Borrowings from financial institutions

 794

 368

 794

Government loans

 193

 193

 193

Lease liabilities

 515

 405

 412

Trade and other payables

4,008

4,112

3,828

Total current liabilities

 5,510

 5,077

 5,227

Total liabilities

 10,423

 11,835

 10,957

Total equity and liabilities

 28,627

 30,722

 31,300

Consolidated statement of changes in shareholders’ equity

Equity attributable to owners of the parent company

In thousands of euro

Share capital

Share premium

Reserve for invested non-restricted equity

Translation differences

Retained earnings

Total

Balance at January 1, 2023

80

504

46,896

51

-27,189

20,342

Comprehensive income

Loss for the period

-2,471

-2,471

Other comprehensive income

Translation differences

244

244

Total comprehensive income for the period

244

-2,471

-2,227

Share options

 16

72

88

Total transactions with owners of the company

16

72

88

Balance at June 30, 2023

80

504

46,912

296

-29,588

18,203

Equity attributable to owners of the parent company

In thousands of euro

Share capital

Share premium

Reserve for invested non-restricted equity

Translation differences

Retained earnings

Total

Balance at January 1, 2022

80

504

38,526

-88

-21,970

17,052

Comprehensive income

Loss for the period

-2,698

-2,698

Other comprehensive income

Translation differences

-120

-120

Total comprehensive income for the period

-120

-2,698

-2,818

Share options

 4,563

91

4,654

Total transactions with owners of the company

4,563

91

4,654

Other adjustments

0

Balance at June 30, 2022

80

504

43,089

-207

-24,577

18,888

Equity attributable to owners of the parent company

In thousands of euro

Share capital

Share premium

Reserve for invested non-restricted equity

Translation differences

Retained earnings

Total

Balance at January 1, 2022

80

504

38,526

-88

-21,970

17,052

Comprehensive income

Loss for the period

-5,472

-5,472

Other comprehensive income

Translation differences

139

139

Total comprehensive income for the period

139

-5,472

-5,333

Share issue

 8,371

8,371

Share options

253

253

Total transactions with owners of the company

8,371

253

8,624

Balance at December 31, 2022

80

504

46,896

51

-27,189

20,342

Consolidated cash flow statement

In thousands of euro

Q2/2023

Q2/2022

H1/2023

H1/2022

2022

Cash flows from operating activities

Loss for the financial year

-1,314

-1,328

-2,471

-2,698

-5,472

Adjustments:

Depreciation, amortization and impairment

losses

547

542

1,076

1,066

3,145

Finance income and finance expenses

333

403

470

330

618

Other adjustments

-44

15

-55

30

-770

Cash flows before change in net working capital

-479

-369

-980

-1,273

-2,479

Change in net working capital:

Change in trade and other receivables

(increase (-) / decrease (+))

-252

-872

-21

-438

204

Change in inventories

(increase (-) / decrease (+))

82

115

-14

-184

-68

Change in trade and other payables

(increase (+) / decrease (-))

223

568

139

671

172

Cash flows before finance items

-426

-557

-875

-1,223

-2,171

Interest paid

-34

-10

-52

-22

-76

Other finance expenses paid

-7

-398

13

-420

-123

Interest received

0

0

0

0

0

Net cash from operating activities (A)

-468

-965

-913

-1,665

-2,370

Cash flows from investing activities

Capitalization of development expenses

-606

-750

-1,124

-1,281

-2,249

Acquisition of tangible assets

-62

-75

-89

-391

-780

Net cash used in investing activities (B)

-668

-825

-1,213

-1,672

-3,029

Cash flows from financing activities

Proceeds from share subscriptions

12

4,892

16

4,945

9,012

Share issue transaction costs

0

-382

0

-382

-682

Proceeds from loans and borrowings

0

14

0

14

0

Repayment of loans and borrowings

-235

-213

-465

-778

-912

Repayment of lease liabilities

-125

-103

-247

-205

-415

Net cash from financing activities (C)

-348

4,208

-696

3,595

7,003

Net cash from (used in) operating, investing and financing activities (A+B+C)

-1,483

2,418

-2,822

257

1,605

Cash and cash equivalents at beginning of period

7,179

4,630

8,524

6,804

6,804

Effect of movements in exchange rate on cash held

-5

31

-11

17

115

Cash and cash equivalents at end of period

5,691

7,079

5,691

7,079

8,524

Selected notes

Corporate information and basis of accounting

Corporate information

Optomed is a Finnish medical technology group (hereafter ‘Optomed’ or ‘Group’) that specialises in handheld fundus cameras and solutions for screening of blinding eye diseases, established in 2004.

The Group’s parent company, Optomed Plc (hereafter the ‘Company’), is a Finnish public limited liability company established under the laws of Finland, and its business ID is 1936446-1. It is domiciled in Oulu, Finland and the Company’s registered address is Yrttipellontie 1, 90230 Oulu, Finland.

Basis of accounting     

Optomed’s consolidated financial statements has been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union. The preparation of this interim report also takes into account the amendments to IFRS standards that have become effective by January 1, 2023.

These interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting and should be read in conjunction with Group`s last annual consolidated financial statements as at and for the year ended 31 December 2022. This Interim financial statements do not include all of the information required by IAS 34: selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group`s financial position and performance since the last annual financial statements.

All presented figures have been rounded so the sum of the individual figures may differ from the presented total figure.

Financial ratios have been calculated using exact figures.

This report has been authorized for issue by the company`s board of directors.

Critical management judgments and related estimates and assumptions                                                                        

The preparation of financial statements under IFRS requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the end of the reporting period as well as the reported amounts of income and expenses during the reporting period. These estimates and assumptions are based on historical experience and other justified assumptions, such as future expectations, that Optomed management believes are reasonable under the circumstances at the end of the reporting period and the time when they were made.                                                                                                                

Although these estimates are based on management’s best knowledge of current events and actions, actual results may ultimately differ from those estimates. The estimates and underlying assumptions are reviewed on an on-going basis and when preparing financial statements. Changes in accounting estimates may be necessary if there are changes in the circumstances on which the estimate was based, or as a result of new information or more experience. Such changes are recognized in the period in which the estimate or the assumption is revised.             

       

Use of judgment and estimates

  

Judgements that management has made in the process of applying accounting policies and that have the most significant effect on the amounts recognised in the financial statements, relate to the following areas:

— Determining trade receivables credit risk

— capitalisation of development costs: determination of development expenditure eligible for capitalisation

— impairment testing of development expenditures

Reportable segments

Q2/2023

In thousands of euro

Devices

Software

Group

Admin

Total

External revenue

 1,273

 2,471

0

 3,744

Net operating expenses

-599

-659

0

-1,258

Margin

674

1,812

0

 2,486

Depreciation and amortization

-360

-184

-2

-547

Other expenses

-891

-1,234

-823

-2,948

Operating result

-578

393

-825

-1,009

Finance items

0

0

-325

-325

Loss before tax expense

-578

393

-1,149

-1,334

Q2/2022

In thousands of euro

Devices

Software

Group

Admin

Total

External revenue

 1,361

 2,372

0

 3,733

Net operating expenses

-719

-865

0

-1,584

Margin

642

1,507

0

 2,149

Depreciation and amortization

-378

-162

-2

-542

Other expenses

-1,106

-1,029

-827

-2,961

Operating result

-843

317

-829

-1,355

Finance items

0

0

6

6

Loss before tax expense

-843

317

-822

-1,348

H1/2023

In thousands of euro

Devices

Software

Group

Admin

Total

External revenue

 2,161

 5,061

0

 7,222

Net operating expenses

-928

-1,332

0

-2,260

Margin

1,233

3,729

0

 4,962

Depreciation and amortization

-713

-359

-4

-1,076

Other expenses

-1,876

-2,362

-1,700

-5,938

Operating result

-1,356

1,009

-1,704

-2,052

Finance items

0

0

-459

-459

Loss before tax expense

-1,356

1,009

-2,163

-2,511

H1/2022

In thousands of euro

Devices

Software

Group

Admin

Total

External revenue

 2,425

 4,522

0

 6,947

Net operating expenses

-1,143

-1,466

0

-2,609

Margin

1,283

3,056

0

 4,339

Depreciation and amortization

-743

-319

-4

-1,066

Other expenses

-2,246

-2,158

-1,685

-6,088

Operating result

-1,707

580

-1,689

-2,815

Finance items

0

0

77

77

Loss before tax expense

-1,707

580

-1,611

-2,738

2022

In thousands of euro

Devices

Software

Group

Admin

Total

External revenue

 5,398

 9,263

0

 14,660

Net operating expenses

-1,659

-2,933

0

-4,592

Margin

3,738

6,330

0

 10,069

Depreciation and amortization

-2,489

-649

-8

-3,145

Other expenses

-4,408

-4,251

-3,361

-12,020

Operating result

-3,159

1,431

-3,368

-5,097

Finance items

0

0

-454

-454

Loss before tax expense

-3,159

1,431

-3,823

-5,551

Revenue

In thousands of euro

Q2/2023

Q2/2022

H1/2023 

H1/2022

2022

Finland

 2,391

2,066

 4,911

 4,172

8,606

Rest of the Europe

234

 682

 470

 997

1,715

Rest of the World

 1,119

 985

 1,841

 1,778

4,340

Total

 3,744

 3,733

 7,222

 6,947

 14,660


Other operating income

In thousands of euro

Q2/2023

Q2/2022

H1/2023

H1/2022

2022

Other operating income

34

0

34

37

857

Total

34

0

34

37

857

Other operating expenses

Other operating expenses

Q2/2023

Q2/2022

H1/2023

H1/2022

2022

Sales and marketing

-192

-204

-339

-378

-784

Research and development

-43

-82

-132

-263

-361

General and administration

-523

-551

-1,085

-1,081

-2,049

Total operating expenses

-758

-838

-1,556

-1,722

-3,193


Other operating expenses also comprise changes in expected credit losses and realized credit losses.

Tangible assets

In thousands of euro

Machinery and equipment 30.6.2023

Machinery and equipment 30.6.2022

Machinery and

equipment 31.12.2022

Cost

Balance at January 1

 3,512

 2,721

 2,721

Additions

 88

 405

 791

Balance at End of Period

 3,600

 3,126

 3,512

Accumulated depreciation and impairment losses

Balance at January 1

-2,660

-2,288

-2,288

Depreciation

-170

-174

-372

Balance at end of period

-2,830

-2,462

-2,660

Carrying amount at January 1

 852

433

 433

Carrying amount at June 30/ December 31

 769

664

 852

Leases

Leased tangible assets

In thousands of euro

30.6.2023

30.6.2022

2022

Additions to right-of-use assets

 280

 35

 671

Depreciation change for right-of-use assets

-253

-211

-428

Carrying amount at the end of the reporting period

1,231

1,029

1,448

Leased tangible assets comprise business premises and are presented as a separate line item Right-of-use assets in the consolidated balance sheet.

Lease liabilities

In thousands of euro

30.6.2023

30.6.2022

2022

Current

 515

 405

 412

Non-current

 744

 640

 1,058

Total

 1,260

 1,044

 1,470

The above liabilities are presented on the line item Lease liabilities (non-current / current) in the consolidated balance sheet, based on their maturity.

Intangible assets and goodwill

30.06.2023

In thousands of euro

Goodwill

Development costs

Customer relationships

Technology

Other intangible assets

Total

Cost

Balance at January 1

4,256

13,978

2,222

1,023

1,054

22,533

Additions

 0 

 1,099

0  

 33

 1,132

Balance at June 30

 4,256

 15,077

 2,222

 1,023

 1,087

 23,665

Accumulated amortization and impairment losses

Balance at January 1

-7,416

-1,057

-489

-676

-9,638

Amortization

 0 

-461

-112

-51

-30

-653

Balance at June 30

-7,877

-1,169

-540

-706

-10,291

Carrying amount at January 1

 4,256

6,562

1,164

534

379

12,895

Carrying amount at June 30

 4,256

 7,200

 1,053

 483

 381

 13,374

30.06.2022

In thousands of euro

Goodwill

Development costs

Customer relationships

Technology

Other intangible assets

Total

Cost

Balance at January 1

 4,256

 11,815

 2,222

 1,023

 951

 20,267

Additions

0

 1,245

0

0

 48

 1,293

Balance at June 30

 4,256

 13,060

 2,222

 1,023

 999

 21,560

Accumulated amortization and impairment losses

Balance at January 1

-5,477

-836

-387

-593

-7,292

Amortization

 0 

-468

-111

-51

-51

-681

Balance at June 30

-5,945

-947

-438

-644

-7,973

 -  

Carrying amount at January 1

 4,256

 6,338

 1,386

 636

 358

 12,975

Carrying amount at June 30

 4,256

 7,115

 1,275

 585

 355

 13,586

31.12.2022

In thousands of euro

Goodwill

Development costs

Customer relationships

Technology

Other intangible assets

Total

Cost

Balance at January 1

 4,256

 11,815

 2,222

 1,023

 951

20,267

Additions

 0  

 2,163

 0  

 0  

 103

2,266

Balance at December 31

 4,256

 13,978

 2,222

 1,023

 1,054

22,533

Accumulated amortization and impairment losses

 -  

Balance at January 1

 0  

-5,477

-836

-387

-593

-7,292

Amortization

 0  

-899

-222

-102

-83

-1,306

Impairment losses

 0  

-1,040

 0  

 0  

 0  

-1,040

Balance at December 31

 0

-7,416

-1,057

-489

-676

-9,638

 -  

Carrying amount at January 1

 4,256

 6,338

 1,386

 636

 358

12,975

Carrying amount at December 31

 4,256

 6,562

 1,164

 534

 379

12,895

Financial assets

Carrying amounts - at amortized cost

In thousands of euro

30.6.2023

30.6.2022

31.12.2022

Trade receivables

Recourse factoring

0

 358

 324

Other trade receivables

 3,442

 3,673

 3,232

Total trade receivables

 3,442

 4,031

 3,556

Cash and cash equivalents

 5,691

 7,079

 8,524

Total

 9,133

 11,109

 12,080

Due to overdue trade receivables, financial assets are subject to an increased risk of credit loss.

Exposure to credit risk and loss allowance

Optomed considers it has heightened risk regarding Chinese customer's trade receivables. The credit risk concentration has been formed and is associated with an increased credit loss risk due to overdue trade receivables. Chinese customer has paid its overdue receivables according to planned schedule.

In thousands of euro

Gross carrying amount

Weighted av.

loss rate%

Loss

allowance

At June 30, 2023

Current (not past due)

                   1,877  

0.5%

                   9  

Past due

1-30 days

                      170  

1.5%

                   3  

31-60 days

                        35  

4%

                   1  

61-90 days

                          8  

9%

                   1  

More than 90 days past due

                      279  

12%

                 33  

Specific loss allowance

                   1,600  

30%

               480  

Total

                   3,970  

               528  

In thousands of euro

Gross carrying amount

Weighted av.

loss rate%

Loss

allowance

At June 30, 2022

Current (not past due)

                   1,800  

0.5%

9

Past due

1-30 days

                      172  

1.5%

3

31-60 days

                        45  

4%

2

61-90 days

                        11  

9%

1

More than 90 days past due

 30

12%

4

Specific loss allowance

 2,332

30%

700

Total

 4,391

 718

In thousands of euro

Gross carrying amount

Weighted av.

loss rate%

Loss

allowance

At December 31, 2022

Current (not past due)

                   1,664  

0.5%

                   8  

Past due

1-30 days

                      161  

1.5%

                   2  

31-60 days

                          7  

4%

                   0  

61-90 days

                        29  

9%

                   3  

More than 90 days past due

                        12  

12%

                   1  

Specific loss allowance

                   1,962  

30%

               589  

Total

                   3,836  

               604  

Financial liabilities

In thousands of euro 

30.6.2023 

30.6.2022 

31.12.2022 

Non-current financial liabilities 

Borrowings from financial institutions

2,983

3,822

3,380

Government loans

837

1,871

906

Lease liabilities

744

640

1,058

Total 

4,565

6,333

5,344

Current financial liabilities 

Borrowings from financial institutions 

794

368

794

Government loans 

193

193

193

Lease liabilities 

515

405

412

Trade payables 

785

1,159

869

Total 

2,287

2,123

2,268

  

Total financial liabilities 

6,852

8,456

7,612

Fair values - financial liabilities measured at amortized cost

Optomed considers that the carrying amounts of the financial liabilities measured at amortized cost substantially equal to their fair values.

Financial covenants

Optomed's borrowings from financial institutions contain a financial covenant (equity ratio) and Optomed also has to meet certain key operative targets.

Optomed has to comply with the financial covenant terms specified in the loan agreement terms at the financial year-end. Equity ratio is calculated using the agreed formula. The table below summarizes the Group's financial covenant term and compliance during the reporting period.

Covenant term

Actual ratio

Applicable level

Nordea loan

At June 30. 2023

Equity ratio

50%

60.9%

Optomed Group

Cash amount

2 million

5.7 million

Optomed Group

At June 30. 2022

Equity ratio

50%

61.5%

Optomed Group

Cash amount

2 million

7.1 million

Optomed Group

At December 31. 2022

Equity ratio

50%

62.1%

Optomed Group

Cash amount

2 million

8.5 million

Optomed Group

OP loan equity ratio

At June 30, 2023

35%

65.3%

Optomed Group

At June 30, 2022

35%

62.7%

Optomed Group

At December 31, 2022

35%

66.1%

Optomed Group

Company’s Equity ratio is calculated as follows depending on the lender:

Nordea loan equity ratio calculation formula:  Adjusted equity/(Balance sheet total+ Leasing liabilities)

OP loan equity ratio calculation formula:  Adjusted equity/(Balance sheet total- received advances)

Optomed was in compliance with the covenant as at June 30, 2023.

Related party transactions

In thousands of euro

Revenues

Trade receivables

Other expenses

Jan 1 - Jun 30 2023

0

0

-40

Jan 1 - Jun 30 2022 

0

0

-40

Jan 1 - Dec 31 2022

0

0

-80

*Comparison figures for Jan1-Jun 30 2022 numbers have been corrected in revenues and trade receivables category.

Revenue and trade receivables and some of the other expenses relate to the major shareholders of Optomed Ltd considered to be related parties to the parent company. Related parties: due to changes in the board of directors, the owners will no longer be related parties in 2022.
 

Other expenses consist of consulting fees paid to the Chairman of the Board of Directors.

Events after the review period

After the review period on 3 August 2023 Optomed announced that Juho Himberg will start as Optomed’s CEO 1 October 2023. Previously Juho Himberg has served as the CEO of Aidian (former Orion Diagnostica), a leading point-of-care diagnostics company with innovative products and services for improving the well-being and quality of life for people around the world. Prior to Aidian, Juho has held several leadership positions globally in healthcare and medical technology companies such as Orton, Stryker, C.R. Bard Inc. and Gambro. The CEO transition plan was announced 14 June 2023. Optomed's current CEO Seppo Kopsala and the Board of Directors have agreed that Kopsala will leave the CEO position once the new CEO is ready to start.